K Number
K163311
Device Name
GMK Revision Femoral Distal Augmentation
Date Cleared
2016-12-21

(28 days)

Product Code
Regulation Number
888.3510
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
The GMK® Total Knee System is designed for cemented use in total knee arthroplasty, if there is evidence of sufficient sound bone to seat and support the components. This knee replacement system is indicated in the following cases: · Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid arthritis or polyarthritis. • Avascular necrosis of femoral condyle. - · Post traumatic loss of joint configuration. - · Primary implantation failure. Tibial wedges cemented are to be attached to the tibial baseplate with both the fixing cylinders and bone cement. The GMK HINGE knee prosthesis is designed for cemented use in total knee arthroplasty when the preoperative diagnosis of the joint determines that the bone and stability situation require the implantation of a constrained prosthesis. The GMK HINGE knee system is indicated in the following cases: · Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid arthritis or polyarthritis associated with bone loss and/or severe joint instability · Considerable loss of function of the knee joint · High-grade joint destruction requiring additional stabilization with stems and reconstruction of bone defects with metal augmentation · Failure of a primary prosthesis (e.g. infection, loosening) · Former revision arthroplasty · Post traumatic loss of joint configuration · Avascular necrosis of femoral condyle. Tibial augmentation are to be screwed to the tibial baseplate with both the two provided fixing screws. When a GMK HINGE® implant is used it is mandatory to implant both the femoral and tibial components with an extension stem.
Device Description
The GMK Revision-Femoral Distal Augmentations have been designed to allow the surgeon to selectively fill bone deficiencies and to aid in adjusting the height of the joint line. In addition, these augments can help to achieve a stable fixation between the implant and the bone. The purpose of this submission is to gain clearance for additional femoral distal augmentation thicknesses of 12 mm, 16 mm, and 20 mm, which can be used with the 5 mm thick posterior wedges. The previously cleared femoral distal augmentation sizes (referred to K102437 as femoral distal wedges) were for 4 mm, 8 mm, and 12 mm. The subject devices are matched with the GMK Revision STD femoral component, GMK Revision PS femoral component and the GMK Hinge femoral component. The distal wedge is fixed to the femoral component through a thickness-specific titanium alloy screw packaged with it. The GMK Revision-Femoral Distal Augmentations are manufactured from high nitrogen stainless steel, which is identical to the predicate device GMK Revision and GMK Hinge femoral distal augmentations (also referred to as wedges) which are available in size range 1-6 with thicknesses of 4 mm, 8 mm, and 12 mm.
More Information

No
The document describes a total knee replacement system and its components, focusing on materials, sizes, and mechanical testing. There is no mention of AI or ML in the intended use, device description, or performance studies.

Yes
Explanation: The device is a knee replacement system intended to treat severe joint pain and disability resulting from various forms of arthritis, avascular necrosis, and post-traumatic loss of joint configuration, which are conditions that impair the body's normal function. By replacing the damaged joint, the device aims to restore function and alleviate pain, thus providing therapy for these conditions.

No

The device description clearly states it is a "Total Knee System," "knee prosthesis," and "femoral distal augmentations" used in knee replacement surgery. These are implants designed for treatment, not for diagnosing a condition.

No

The device description clearly describes physical components made of high nitrogen stainless steel and titanium alloy, which are hardware.

Based on the provided text, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use clearly describes a surgical implant for total knee arthroplasty to address various knee joint conditions. This is a therapeutic intervention performed in vivo (within the body).
  • Device Description: The device is described as a physical implant (femoral distal augmentations) made of stainless steel, designed to be surgically attached to other components of a knee replacement system.
  • Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or compatibility testing.

IVD devices are used in vitro (outside the body) to analyze biological samples. This device is a surgical implant used in vivo.

N/A

Intended Use / Indications for Use

The GMK Total Knee System is designed for cemented use in total knee arthroplasty, if there is evidence of sufficient sound bone to seat and support the components.

This knee replacement system is indicated in the following cases:

· Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid arthritis or polyarthritis.
• Avascular necrosis of femoral condyle.

  • · Post traumatic loss of joint configuration.
  • · Primary implantation failure.

Tibial wedges cemented are to be attached to the tibial baseplate with both the fixing cylinders and bone cement.

The GMK HINGE knee prosthesis is designed for cemented use in total knee arthroplasty when the preoperative diagnosis of the joint determines that the bone and stability situation require the implantation of a constrained prosthesis.

The GMK HINGE knee system is indicated in the following cases:

· Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid arthritis or polyarthritis associated with bone loss and/or severe joint instability
· Considerable loss of function of the knee joint
· High-grade joint destruction requiring additional stabilization with stems and reconstruction of bone defects with metal augmentation
· Failure of a primary prosthesis (e.g. infection, loosening)
· Former revision arthroplasty
· Post traumatic loss of joint configuration

  • Avascular necrosis of femoral condyle.
    Tibial augmentation are to be screwed to the tibial baseplate with both the two provided fixing screws.

When a GMK HINGE® implant is used it is mandatory to implant both the femoral and tibial components with an extension stem.

Product codes (comma separated list FDA assigned to the subject device)

KRO, JWH

Device Description

The GMK Revision-Femoral Distal Augmentations have been designed to allow the surgeon to selectively fill bone deficiencies and to aid in adjusting the height of the joint line. In addition, these augments can help to achieve a stable fixation between the implant and the bone.

The purpose of this submission is to gain clearance for additional femoral distal augmentation thicknesses of 12 mm, 16 mm, and 20 mm, which can be used with the 5 mm thick posterior wedges. The previously cleared femoral distal augmentation sizes (referred to K102437 as femoral distal wedges) were for 4 mm, 8 mm, and 12 mm.

The subject devices are matched with the GMK Revision STD femoral component, GMK Revision PS femoral component and the GMK Hinge femoral component. The distal wedge is fixed to the femoral component through a thickness-specific titanium alloy screw packaged with it.

The GMK Revision-Femoral Distal Augmentations are manufactured from high nitrogen stainless steel, which is identical to the predicate device GMK Revision and GMK Hinge femoral distal augmentations (also referred to as wedges) which are available in size range 1-6 with thicknesses of 4 mm, 8 mm, and 12 mm.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Knee joint

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Non-Clinical Studies

  • Femoral Modular Connection- GMK-Revision Knee
  • Femoral Modular Connection- GMK-Hinge Knee
  • Limulus Amebocyte Lysate (LAL) testing was evaluated to establish the device meets pyrogen limit specifications.

Medacta previously conducted testing of the GMK Revision Femoral Component Size 1, GMK Revision Femoral Distal Wedge/ Augmentation Size 1 and GMK Revision Posterior Wedges Size 1, which are considered the worst-case product configuration as they have the least contact area, which makes the implant less able to fixate with cement. The results of the original testing showed that the worst-case product configuration is able to withstand physiological loads without any breakage and minimal fretting. The connection was stable and fixed after subjected to dynamic loading conditions. Since the femoral component, femoral distal wedge/augmentation and posterior wedges must all be the same size when implanted it is determined that the worst case remains unchanged. The data was previously submitted in the predicate 510(k) K102437. The test performed on the modular connection of the GMK-Revision implant are also applicable to the GMK-Hinge Femoral Component.

The Femoral Distal Augmentations 12 mm. 16 mm and 20 mm do not represent a worst-case configuration in terms of connection with the femoral components. The application of the load and the screwed connection are the same for all thicknesses.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K102437

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

K130299

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 888.3510 Knee joint femorotibial metal/polymer constrained cemented prosthesis.

(a)
Identification. A knee joint femorotibial metal/polymer constrained cemented prosthesis is a device intended to be implanted to replace part of a knee joint. The device limits translation or rotation in one or more planes and has components that are linked together or affined. This generic type of device includes prostheses composed of a ball-and-socket joint located between a stemmed femoral and a stemmed tibial component and a runner and track joint between each pair of femoral and tibial condyles. The ball-and-socket joint is composed of a ball at the head of a column rising from the stemmed tibial component. The ball, the column, the tibial plateau, and the stem for fixation of the tibial component are made of an alloy, such as cobalt-chromium-molybdenum. The ball of the tibial component is held within the socket of the femoral component by the femoral component's flat outer surface. The flat outer surface of the tibial component abuts both a reciprocal flat surface within the cavity of the femoral component and flanges on the femoral component designed to prevent distal displacement. The stem of the femoral component is made of an alloy, such as cobalt-chromium-molybdenum, but the socket of the component is made of ultra-high molecular weight polyethylene. The femoral component has metallic runners which align with the ultra-high molecular weight polyethylene tracks that press-fit into the metallic tibial component. The generic class also includes devices whose upper and lower components are linked with a solid bolt passing through a journal bearing of greater radius, permitting some rotation in the transverse plane, a minimal arc of abduction/adduction. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).(b)
Classification. Class II.

0

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a symbol of three stylized human profiles facing to the right, with three wave-like lines below them.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

December 21, 2016

Medacta International SA Ms. Elizabeth Rose Manager, Regulatory Affairs Mapi USA, Inc. 2343 Alexandria Drive Suite 100 Lexington, Kentucky 40504

Re: K163311

Trade/Device Name: GMK Revision-Femoral Distal Augmentation Regulation Number: 21 CFR 888.3510 Regulation Name: Knee joint femorotibial metal/polymer constrained cemented prosthesis Regulatory Class: Class II Product Code: KRO, JWH Dated: November 23, 2016 Received: November 23, 2016

Dear Ms. Rose:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

1

the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

Lori A. Wiggins -S

for

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known)

K163311

Device Name

GMK Revision-Femoral Distal Augmentation

Indications for Use (Describe)

The GMK® Total Knee System is designed for cemented use in total knee arthroplasty, if there is evidence of sufficient sound bone to seat and support the components.

This knee replacement system is indicated in the following cases:

· Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid arthritis or polyarthritis.

• Avascular necrosis of femoral condyle.

  • · Post traumatic loss of joint configuration.
  • · Primary implantation failure.

Tibial wedges cemented are to be attached to the tibial baseplate with both the fixing cylinders and bone cement.

Type of Use (Select one or both, as applicable)
---------------------------------------------------

X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known)

Device Name

GMK Revision- Femoral Distal Augmentation

Indications for Use (Describe)

The GMK HINGE knee prosthesis is designed for cemented use in total knee arthroplasty when the preoperative diagnosis of the joint determines that the bone and stability situation require the implantation of a constrained prosthesis.

The GMK HINGE knee system is indicated in the following cases:

· Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid arthritis or polyarthritis associated with bone loss and/or severe joint instability

· Considerable loss of function of the knee joint

· High-grade joint destruction requiring additional stabilization with stems and reconstruction of bone defects with metal augmentation

· Failure of a primary prosthesis (e.g. infection, loosening)

· Former revision arthroplasty

· Post traumatic loss of joint configuration

· Avascular necrosis of femoral condyle.

Tibial augmentation are to be screwed to the tibial baseplate with both the two provided fixing screws.

When a GMK HINGE® implant is used it is mandatory to implant both the femoral and tibial components with an extension stem.

Type of Use (Select one or both, as applicable)
-------------------------------------------------
☑ Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)
------------------------------------------------------------------------------------------------------------------------------------------------

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

4

3.0 510(k) Summary

I. Submitter

Medacta International SA Strada Regina 6874 Castel San Pietro (CH) Switzerland Phone (+41) 91 696 60 60 Fax (+41) 91 696 60 66

Contact Person: Stefano Baj, Regulatory Affairs Manager Date Prepared: November 23, 2016

II. Device

Device Proprietary Name:GMK Revision-Femoral Distal Augmentation
Common or Usual Name:Total knee prosthesis
Classification Name:Prosthesis knee, Femorotibial, Constrained Cemented,
Metal/Polymer
Knee joint, patellofemorotibial polymer/metal/polymer sem
constrained cemented prosthesis
Regulation Number:21 CFR 888.3510
21 CFR 888.3560
Product Code:KRO
JWH
Device Classification2

III. Predicate Device

Substantial equivalence is claimed to the following devices:

Primary Predicate:

  • . GMK Revision, K102437, Medacta International SA
    Reference Predicate

  • GMK Hinge, K130299, Medacta International SA .

Device Description IV.

The GMK Revision-Femoral Distal Augmentations have been designed to allow the surgeon to selectively fill bone deficiencies and to aid in adjusting the height of the joint line. In addition, these augments can help to achieve a stable fixation between the implant and the bone.

5

The purpose of this submission is to gain clearance for additional femoral distal augmentation thicknesses of 12 mm, 16 mm, and 20 mm, which can be used with the 5 mm thick posterior wedges. The previously cleared femoral distal augmentation sizes (referred to K102437 as femoral distal wedges) were for 4 mm, 8 mm, and 12 mm.

The subject devices are matched with the GMK Revision STD femoral component, GMK Revision PS femoral component and the GMK Hinge femoral component. The distal wedge is fixed to the femoral component through a thickness-specific titanium alloy screw packaged with it.

The GMK Revision-Femoral Distal Augmentations are manufactured from high nitrogen stainless steel, which is identical to the predicate device GMK Revision and GMK Hinge femoral distal augmentations (also referred to as wedges) which are available in size range 1-6 with thicknesses of 4 mm, 8 mm, and 12 mm.

V. Indications for Use

The GMK® Total Knee System is designed for cemented use in total knee arthroplasty, if there is evidence of sufficient sound bone to seat and support the components.

This knee replacement system is indicated in the following cases:

  • Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid ● arthritis or polyarthritis.
  • . Avascular necrosis of femoral condyle.
  • Post traumatic loss of joint configuration.
  • Primary implantation failure.

Tibial wedges cemented are to be attached to the tibial baseplate with both the fixing cylinders and bone cement.

The GMK HINGE knee prosthesis is designed for cemented use in total knee arthroplasty when the preoperative diagnosis of the joint determines that the bone and stability situation require the implantation of a constrained prosthesis.

The GMK HINGE knee system is indicated in the following cases:

  • Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid ● arthritis or polyarthritis associated with bone loss and/or severe joint instability
  • Considerable loss of function of the knee joint
  • . High-grade joint destruction requiring additional stabilization with stems and reconstruction of bone defects with metal augmentation
  • Failure of a primary prosthesis (e.g. infection, loosening)
  • Former revision arthroplasty
  • Post traumatic loss of joint configuration ●

6

  • Avascular necrosis of femoral condyle. .
    Tibial augmentation are to be screwed to the tibial baseplate with both the two provided fixing screws.

When a GMK HINGE® implant is used it is mandatory to implant both the femoral and tibial components with an extension stem.

VI. Comparison of Technological Characteristics

The GMK Revision-Femoral Distal Augmentations and the predicate devices share the following characteristics:

  • Indications for Use ●
  • Materials
  • Packaging ●
  • Design
  • Use with both GMK Revision and GMK Hinge Femoral Components ●
  • Sterile ●

The GMK Revision-Femoral Distal Augmentations is technologically different from the predicate devices as follows:

  • Thickness sizes available
  • Change to 12 mm augmentation, reduction in posterior side only ●

Biocompatibility testing conducted on the predicate device for the same material supports the biological safety of the GMK Revision-Femoral Distal Augmentations. Additional testing was not deemed necessary.

A comparison of the subject and predicate devices is provided in the table below.

Technological comparison

ParametersFemoral Distal Augmentation (Subject Device)GMK Revision Femoral Distal Wedge K102437 (Predicate Device)
Design/TypesDistal femoral wedge with connection screwDistal femoral wedge with connection screw
MaterialHigh Nitrogen Stainless Steel (M30NW)High Nitrogen Stainless Steel (M30NW)
SizesSizes 1-6Sizes 1-6
Thickness12 mm, 16 mm, 20 mm4 mm, 8 mm, 12 mm
Compatibility with implant systemGMK Revision and GMK HingeGMK Revision and GMK Hinge
Device usageSingle UseSingle Use
Shelf Life5 years5 years

7

| Parameters | Femoral Distal
Augmentation (Subject
Device) | GMK Revision Femoral
Distal Wedge
K102437
(Predicate Device) |
|------------------|---------------------------------------------------------------|-----------------------------------------------------------------------|
| Biocompatibility | Implant with permanent >30
day
(Equivalency determined) | Implant with permanent >30
day |
| Sterilization | Gamma | Gamma |
| Packaging | Individual packaging | Individual packaging |

Discussion

As seen above, the differences between the subject and predicate devices are the subject device are thicker than the predicate device. This technological difference does not raise new questions of safety or effectiveness and a comparison evaluation shows there are no new risks associated with the subject device design.

VII. Performance Data

The following performance data were provided in support of the substantial equivalence determination.

Non-Clinical Studies

  • Femoral Modular Connection- GMK-Revision Knee
  • Femoral Modular Connection- GMK-Hinge Knee ●
  • Limulus Amebocyte Lysate (LAL) testing was evaluated to establish the device meets ● pyrogen limit specifications.

Medacta previously conducted testing of the GMK Revision Femoral Component Size 1, GMK Revision Femoral Distal Wedge/ Augmentation Size 1 and GMK Revision Posterior Wedges Size 1, which are considered the worst-case product configuration as they have the least contact area, which makes the implant less able to fixate with cement. The results of the original testing showed that the worst-case product configuration is able to withstand physiological loads without any breakage and minimal fretting. The connection was stable and fixed after subjected to dynamic loading conditions. Since the femoral component, femoral distal wedge/augmentation and posterior wedges must all be the same size when implanted it is determined that the worst case remains unchanged. The data was previously submitted in the predicate 510(k) K102437. The test performed on the modular connection of the GMK-Revision implant are also applicable to the GMK-Hinge Femoral Component.

The Femoral Distal Augmentations 12 mm. 16 mm and 20 mm do not represent a worst-case configuration in terms of connection with the femoral components. The application of the load and the screwed connection are the same for all thicknesses.

8

Medacta does not intend to make a claim of "non-pyrogenic" on the device labeling for the Femoral Distal Augmentations.

VIII. Conclusion

The information provided above supports that the GMK Revision-Femoral Distal Augmentations are as safe and effective as the predicate devices. The addition of the new thicknesses of the subject device as compared to the predicate device, do not raise any new questions of safety and effectiveness. Therefore, it is concluded that the GMK Revision-Femoral Distal Augmentations are substantially equivalent to the predicate devices.

-------------------------------This space intentionally left blank------------------------------------------------------------------------------------------------------------